Redefining MDR-TB transmission 'hot spots'

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 5, 2000, Pages 387-394

  Becerra, Mercedes C ^a,b   Bayona, J ^a   Freeman, J ^b   Farmer, P E ^a   Kim, J Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

'Hot spots'; DOTS Plus; MDR TB; Priority setting; Transmission; Tuberculosis

Indexed keywords

ARTICLE; DISEASE TRANSMISSION; HEALTH CARE PLANNING; HUMAN; INFECTION CONTROL; INFECTION RISK; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; ENDEMIC DISEASES; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; MALE; POPULATION SURVEILLANCE; PRIMARY PREVENTION; RISK FACTORS; SURVIVAL RATE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 0034021474     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Klaudt K. Use DOTS more widely. TB Treatment Observer, March 24, 1997; 4: 2.
2. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/TB/97.229. Geneva: World Health Organization, 1997.
3. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for anti-tuberculosis drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
4. World Health Organization. WHO Report on the Tuberculosis Epidemic. WHO/TB/97.224. Geneva: World Health Organization, 1997.
5. Farmer P E, Bayona J, Becerra M, et al. The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
6. Farmer P E, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". Brit Med J 1998; 317: 671-674.
7. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
8. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142: 1301-1305.
9. Espinal M A, Kim S J, Hong Y P, et al. Treatment outcome of multidrug resistant (MDR) tuberculosis (TB) cases under programme conditions. Int J Tuberc Lung Dis 1998; 2 (Suppl 2): S371-S372.
10. Farmer P E. Managerial successes, clinical failures. Int J Tuberc Lung Dis 1999; 3: 365-367.
11. Iseman M D. MDR-TB and the developing world - a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis 1998; 2: 867.
12. World Health Organization. Coordination of DOTS-Plus pilot projects for the management of MDR-TB. WHO/CDS/CBC/ TB/99.262. Geneva: World Health Organization, 1999.
13. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/TB/96.199. Geneva, Switzerland: World Health Organization; 1996.
14. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 122842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
15. Freeman J, Hutchison G B. Prevalence, incidence and duration. Am J Epidemiol 1980; 112: 707-723.
16. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-686.
17. Espinal M A, Dye C, Raviglione M C, Kochi A. Rational 'DOTS Plus' for the control of MDR-TB. Int J Tuberc Lung Dis 1999; 3: 561-563.
18. Farmer P E, Furin J J, Bayona J, et al. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis 1999; 3: 643-645.
19. Rothman K J. Modern epidemiology. Boston, MA: Little, Brown, and Company, 1996.
20. Espinal M A, Simonsen L, WHO/IUATLD Working Group on Drug Resistance Surveillance. Global trends in drug-resistant tuberculosis. Int J Tuberc Lung Dis 1999; 3 (Suppl 1): S7.
21. Blower S M, McLean A R, Porco T C, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nature Med 1995; 1: 815-821.
22. Alland D, Kalkut G E, Moss A R, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
23. Selwyn P A, Sckell B M, Alcabes P, Friedland G H, Klein R S, Schoenbaum E E. High risk of active tuberculosis in HIV infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
24. Cantwell M, Binkin N. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis 1997; 1: 205-214.
25. Schulzer M, Fitzgerald J M, Enarson D A, Grzybowski S. An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HIV infection. Tubercle Lung Dis 1992; 73: 52-58.
26. Hopewell P C, Sanchez-Hernandez M, Baron R B, Ganter B. Operational evaluation of treatment for tuberculosis. Results of a 'standard' 12-month regimen in Peru. Am Rev Respir Dis 1984; 129: 439-443.
27. Hopewell P C, Ganter B, Baron R B, Sanchez-Hernandez M. Operational evaluation of treatment for tuberculosis. Results of 8-and 12-month regimens in Peru. Am Rev Respir Dis 1985; 132: 737-741.
28. Iseman M. Tailoring a time bomb: inadvertent genetic engineering. Am Rev Respir Dis 1985; 132: 735-736.
29. World Health Organization. Groups at risk. WHO report on the tuberculosis epidemic. WHO/TB/96.198. Geneva: World Health Organization, 1996.
30. Ministerio de Salud. Tuberculosis en el Peru -Informe 1997. Lima, Peru: Ministerio de Salud, 1998.
31. Farmer P E, Kononets A S, Borisov S E, Goldfarb A, Healing T, McKee M. Recrudescent tuberculosis in the Russian Federation. In: The Global Impact of Drug-Resistant Tuberculosis. Boston, MA; Harvard Medical School and the Open Society Institute, 1999.
32. Kimerling M E, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDRTB. Int J Tuberc Lung Dis 1999; 3: 451-453.
33. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3: 582-588.
34. Coninx R, Pfyffer G E, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. Brit Med J 1998; 316: 1423-1425.
35. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2000; 4: 108-114.
36. Kim J Y, Furin J J, Shakow A D, et al. Treatment of multidrug-resistant tuberculosis (MDR-TB): new strategies for procuring second-line drugs. Int J Tuberc Lung Dis 1999; 3 (Suppl 1): S81.
37. Kim J Y, Milieu J V, Irwin A, Gershman J, eds. Dying for growth: global inequality and the health of the poor. Monroe, ME: Common Courage Press, 2000.
38. Farmer P E. Social inequalities and emerging infectious diseases. Emerg Infect Dis 1996; 2: 259-269.
39. Bifani P J, Plikaytis B B, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452-457.
40. Agerton T B, Valway S E, Blinkhorn R J, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999; 29: 85-92.
41. Casper C, Singh S P, Rave S, et al. The transcontinental transmission of tuberculosis: a molecular epidemiological assessment. Am J Public Health 1996; 86: 551-553.
42. Codina G, Vidal R, Martin-Casabona N, Miravitlles M, Martin C. Multidrug-resistant tuberculosis caused by 'W'-related strains in three immunocompetent foreign-born patients. Int J Tuberc Lung Dis 1999; 3: 82-83.
43. Borchardt J, Kirsten D, Jörres R, Kroeger C, Magnussen H. Drug-resistant tuberculosis in Northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. Eur Respir J 1995; 8: 1076-1083.
44. Lambregts-van Weezenbeek C S B, Jansen H M, Nagelkerke N J D, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcomes. Int J Tuberc Lung Dis 1998; 2: 288-295.
45. Codecasa L R, Porretta A D, Gori A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996. Int J Tuberc Lung Dis 1999; 3: 589-595.
46. Hauer B, Serke M, Loddenkemper R, Roth A, Fischer M, Mauch H. Various polyresistant strains of M. tuberculosis in one patient (case report). Int J Tuberc Lung Dis 1999; 3 (Suppl 1): S122.
47. Timperi R, Sloutsky A, Farmer P E. Global laboratory testing capacity for tuberculosis. Int J Tuberc Lung Dis 1998; 2: S290-S291.
48. Heifets L B, Cangelosi G A. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581.
49. Salomon N, Perlman D C. Multidrug-resistant tuberculosis-globally with us for the long haul. Clin Infect Dis 1999; 29: 93-95.
50. Farmer P E, Becerra M C, Kim J Y. Conclusions and recommendations. In: The Global Impact of Drug-Resistant Tuberculosis. Boston, MA: Harvard Medical School and the Open Society Institute, 1999.